Pilot Study of Leuprorelin for Gynecologic Malignancies

Pilot Study of Leuprorelin for Gynecologic Malignancies - Leuprorelin for Gynecologic Malignancies

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001561

Enrollment

Registered

2008-12-10

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced / recurrent gynecologic malignancies

Interventions

leuprolerin S.C.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) refractory/ resistant Mullerian carcinoma(epithelial ovarian carcinoma, tubal carcinoma, and primary peritoneal carcinoma) 2) advanced/ recurrent other gynecologic malignancies

Exclusion criteria

Exclusion criteria: Performance status > 2 (ECOG)

Design outcomes

Primary

Measure	Time frame
Symtom stabilization at 8 weeks	—

Secondary

Measure	Time frame
progression free survival, overall survival, response rate, qaulity of life	—

Countries

Japan

Contacts

Public ContactHiroshi Tsubamoto

Hyogo College of Medicine Obstetrics and Gynecology

tsuba@hyo-med.ac.jp0798-45-6481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026